Biaryl compositions and methods for modulating a kinase cascade

Details Biaryl compositions and methods for modulating a kinase cascade Biaryl compositions and methods for modulating a kinase cascade

2011-06-28

2011-06-28

Kosack, Joseph R (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S235500, C514S340000, C546S268400, C546S337000, C544S131000

Reexamination Certificate

active

07968574

ABSTRACT:
The invention relates to compounds and methods for modulating one or more components of a kinase cascade. The invention relates to compounds of the formula I:or a pharmaceutically acceptable salt thereof. The compounds of the invention are useful for methods of protecting against or treating hearing loss, osteoporosis, cell proliferative disorders, obesity, diabetes, eye disease, stroke, atherosclerosis, neuropathic pain or hepatitis B.

REFERENCES:
patent: 3868380 (1975-02-01), Molteni et al.
patent: 4010279 (1977-03-01), Griss et al.
patent: 6538960 (2003-03-01), Sabi et al.
patent: 6624180 (2003-09-01), South et al.
patent: 6844367 (2005-01-01), Zhu et al.
patent: 6969726 (2005-11-01), Lou et al.
patent: 2004/0242572 (2004-12-01), Stenkamp et al.
patent: 2005/0043317 (2005-02-01), Zhou et al.
patent: 2005/0059713 (2005-03-01), Mjalli et al.
patent: 2006/0100245 (2006-05-01), Bakthavatchalam et al.
patent: 2006/0160800 (2006-07-01), Hangauer, Jr.
patent: 0 463 638 (1992-01-01), None
patent: WO 9219208 (1992-11-01), None
patent: WO 96/12473 (1996-05-01), None
patent: WO 99/01127 (1999-01-01), None
patent: WO 01/19788 (2001-03-01), None
patent: WO 01/85726 (2001-11-01), None
patent: WO 02/079197 (2002-10-01), None
patent: WO 03/059903 (2003-07-01), None
patent: WO 03/078404 (2003-09-01), None
patent: WO 03/087057 (2003-10-01), None
patent: WO 03/093248 (2003-11-01), None
patent: WO 03/093297 (2003-11-01), None
patent: WO 2004/011427 (2004-02-01), None
patent: WO 2004/056774 (2004-07-01), None
patent: WO 2004056774 (2004-07-01), None
patent: WO 2005/013914 (2005-02-01), None
patent: WO 2005/032493 (2005-04-01), None
patent: WO 2006/071960 (2006-07-01), None
patent: WO 2007/026920 (2007-03-01), None
patent: WO 2007/095383 (2007-08-01), None
Homma et al. J. Med. Chem. 1983, 26, 1499-1504.
Davidson et al., “Discovery and characterization of a substrate selective p38α inhibitor”,Biochemistry, 43:11658-11671 (2004).
Cain et al., “Potential Antitumor Agents. IX. Bisquaternary Salts”,J. Med. Chem.,11(5):963-966 (1968).
Liechti et al., “Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor”,Eur. J. Med. Chem., 39(1):11-26 (2004).
Million et al., “Inhibition of the EGF-stimulated cellular proliferation of ER 22 cells by hydroxybiphenyl derivatives”,J. Med. Chem., 38(23):4693-4703 (1995).
Zhng et al., “Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs”,Bioorg. Med. Chem. Lett., 14(4):983-987 (2004).
Duong et al., “Inhibition of osteoclast function by adenovirus expressing Antisense protein-tyrosine kinase 2”,J. Biol. Chem., 276(10):7484-7492 (2001).
Frame, M.C., “Src in cancer:deregulation and consequences for cell behaviour”,Biochem. Biophys. Acta, 1602:114-130 (2002).
Guo et al., “Tyrosine phosphorylation of the NR2B subunit of the NMDA receptor in the spinal cord during the development and maintenance of inflammatory hyperalgesia”,J. Neurosci., 22(14):6208-6217 (2002).
Hadjeri et al., “Antimitotic activity of 5-hydroxy-7-methoxy-2-phenyl-4-quinolones”.J. Med. Chem., 47:4964-4970 (2004).
Miyazaki et al., “Src kinase activity is essential for osteoclast function”,J. Biol. Chem., 279(17):17660-17666 (2004).
Parang et al., “Recent advances in the discovery of Src kinase inhibitors”,Expert Opin. Ther. Patents, 15(9):1183-1207 (2005).
Paul et al., “Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke”,Nat. Med., 7(2):222-227 (2001).
Yu et al., “Src, a molecular switch governing gain control of synaptic transmission mediated by N-methyl-D-aspartate receptors”, Proc. Natl. Acad. Sci. USA, 96:7697-7704 (1999).

Affiliated with

Also associated with

Rating

Biaryl compositions and methods for modulating a kinase cascade does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Biaryl compositions and methods for modulating a kinase cascade, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biaryl compositions and methods for modulating a kinase cascade will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2651537